Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of ACP-105 and Ligandrol (LGD-4033) — mechanism, side effects, legal status, and pricing.
ACP-105 is a non-peptide nonsteroidal selective androgen receptor modulator (SARM) of the azabicyclooctane chemotype, structurally related to AC-262536 and RAD140. It acts as a partial agonist at the androgen receptor with tissue-selective anabolic effects demonstrated in preclinical models. ACP-105 is not an approved drug in any jurisdiction and has never entered human clinical trials. SARMs as a class are prohibited at all times under WADA Prohibited List S1.2 'Other Anabolic Agents'; ACP-105 falls under this class-wide ban and has been the subject of equine anti-doping metabolite-detection research.
Ligandrol (LGD-4033) is a nonsteroidal selective androgen receptor modulator (SARM) of the substituted pyrrolidinyl-benzonitrile chemotype. It has been tested in Phase 1 and Phase 2 clinical trials for muscle wasting and hip-fracture recovery but has no FDA-approved medical use anywhere. LGD-4033 is prohibited at all times (in- and out-of-competition) under WADA Prohibited List section S1.2, “Other Anabolic Agents” (SARMs class). It is sold online as an unregulated “research chemical” of unverified purity and dose.
ACP-105
Ligandrol (LGD-4033)
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
ACP-105
Ligandrol (LGD-4033)
No pricing data yet.
Check Ligandrol (LGD-4033) prices →COA corpus from Disclosed Labs — independently tested batches only.
ACP-105
2
COAs
99.3%
Avg purity
1
Labs
Ligandrol (LGD-4033)
2
COAs
99.4%
Avg purity
1
Labs
No human data exist for ACP-105. In castrated male rats, 2-week oral dosing improved anabolic parameters consistent with tissue-selective partial AR agonism, suppressed the LH surge, and produced levator ani muscle anabolic effects. In female mice (whole-body irradiated and sham-irradiated), ACP-105 preserved rotorod sensorimotor performance impaired by radiation and enhanced cued fear conditioning while reducing MAP-2 immunoreactivity in sensorimotor cortex. In male gonadectomized 3xTg-AD Alzheimer's-model mice, ACP-105 alone reduced anxiety-like behavior; combined with the ER-beta agonist AC-186, it improved cognition (Morris water maze), increased amyloid-beta-degrading enzymes (neprilysin, IDE), and decreased brain amyloid-beta versus vehicle. Equine in vitro liver microsome studies identified twelve Phase I metabolites for doping-control detection purposes.
Key references
Human data are limited to investigational trials and case reports; no approved medical use exists. A Phase 1 randomized, double-blind, placebo-controlled trial (Basaria et al. 2013, N=76 healthy men aged 21–50) tested 0.1, 0.3, and 1.0 mg/day for 21 days and found dose-dependent increases in lean body mass, with dose-dependent suppression of testosterone, SHBG, HDL cholesterol, and triglycerides that normalized after stopping. A Phase 2 trial (VK5211, N=108 hip-fracture-recovery patients, 0.5–2.0 mg/day for 12 weeks) reported via press release placebo-adjusted lean-mass increases of 4.8–9.1% with no drug-related serious adverse events; this result has not been peer-reviewed. Published case reports document severe cholestatic hepatitis (total bilirubin 35.0 mg/dL) in a 32-year-old male after ∼10 mg/day for ∼2 weeks—a dose 10–100× higher than trial doses—and marked testosterone suppression (−62.3%), elevated liver enzymes (ALT +205%, AST +96%), and adverse lipid changes in a 25-year-old male using 10 mg/day for 5 weeks; both cases involved unsupervised gray-market product. In ovariectomized rats (osteoporosis model), oral LGD-4033 at 0.04–4 mg/kg/day for 5 weeks increased muscle capillary density at all doses, elevated oxidative enzymes at intermediate doses, and increased muscle fiber cross-sectional area at the highest dose, but also increased intramuscular fat and uterine weight at 4 mg/kg, indicating loss of tissue selectivity at high exposure.
ACP-105 and Ligandrol (LGD-4033) are both in the Performance category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Key references
Disclosed Labs